Ofatumumab is more effective than teriflunomide for relapsing multiple sclerosis across subgroups<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, July 17, 2024 (HealthDay News) — For patients with relapsing multiple sclerosis (RMS), ofatumumab is more effective than teriflunomide across racial and ethnic subgroups, according to a study published online July 17 in Neurology<\/em>.<\/p>\n Mitzi J. Williams, M.D., from the Joi Life Wellness MS Center in Atlanta, and colleagues conducted a post-hoc analysis to compare the proportion of patients with RMS achieving three-parameter no evidence of disease activity (NEDA-3) with ofatumumab versus teriflunomide. A total of 1,882 participants were randomly allocated to receive ofatumumab 20 mg every four weeks or teriflunomide 14 mg once daily for up to 30 months.<\/p>\n The researchers found that from months 0 to 24, the proportion of ofatumumab- versus teriflunomide-treated patients achieving NEDA-3 was 33.3 versus 3.4 percent for non-Hispanic Black patients; 42.9 versus 21.9 percent for non-Hispanic Asian patients; 36.6 versus 18.6 percent for Hispanic\/Latino patients; and 37.4 versus 16.6 percent for non-Hispanic White patients. Between treatment group and across race\/ethnicity subgroups, the rates of adverse events were generally similar; no new or unexpected safety signals were seen.<\/p>\n “Our study examined the efficacy and safety of ofatumumab in diverse populations,” Williams said in a statement. “We found overall the drug was effective and safe across racial and ethnic groups.”<\/p>\n Several authors disclosed ties to pharmaceutical companies, including Novartis, which manufactures ofatumumab and funded the study.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n